NEW YORK, April 2, 2013 /PRNewswire-iReach/ -- A study published in the Journal of Medicinal Food, on research conducted at the Diabetes and Glandular Disease Clinic, a recognized Center of Excellence by the American Diabetes Association, has shown that taking Emulin(TM) decreased blood glucose levels by up to 20 percent. These results state that Emulin is effective in reducing blood glucose in type 2 diabetics.
"The study confirms that Emulin(TM), if consumed regularly, could not only have the acute effect of lowering the glycemic impact of foods but chronically lower background blood glucose levels of type 2 diabetics" says Dr. Joseph Ahrens.
In the trial, participants with confirmed type 2 diabetes were divided into one of four groups: Emulin(TM) /no medication; placebo/metformin; placebo/Emulin(TM); Emulin(TM) /metformin. Emulin(TM) performed equal to or better than metformin, the most widely prescribed drug for diabetes. The most significant reduction in blood glucose occurred in the participants in the Emulin(TM) /metformin group, demonstrating the efficacy of Emulin(TM) in decreasing blood glucose in type 2 diabetics. This finding suggests that Emulin(TM) may be effective for weight-loss and weight management.
"Emulin(TM) is the most functional supplement for diabetics that we've ever seen in the marketplace. It's truly revolutionary," says Russ Anderson, President of Anderson Global Group. "We're pleased to partner with VREV LIMITED, to ensure Emulin(TM) helps as many people as possible."
As part of an exclusive arrangement with ATM Metabolics, LLC, VREV LIMITED, has entered a partnership with Anderson Global Group, LLC (AGG), to be the exclusive supplier of the patented Emulin(TM) formulation.
"We saw how effective Emulin(TM) is and through Diabetix and GC7X, our over-the-counter products can help thousands of health and weight conscious people." says Andrew Nagy, director, media relations, VREV LIMITED. "This study confirms what we've heard from our customers, Emulin(TM) works."
The study is available in the Journal of Medicinal Food.
About VREV LIMITED:
VREV LIMITED offers full-service product sales and multi-channel retail distribution solutions and holds the exclusive distribution rights to Emulin(TM) throughout North America. The VREV portfolio currently includes diabetix(TM) and GC7X (TM). For more information please visit: www.getdiabetix.com and www.gc7x.com.
About Anderson Global Group, LLC:
Anderson Global Group, LLC (AGG), based in Irvine, California, provides premium functional ingredients to the nutraceutical, food, beverage and cosmaceutical markets. The AGG portfolio features Emulin(TM) Sugar Defense Blend, Provinal(TM) Purified Omega 7 Oil, Solutex Supercriticum(TM) Omega 3 Oils, CherryPURE(TM) Tart Cherry Powder, Polycan(TM) Bone Support Complex, VitaFiber(TM) Isomalto Oligosaccharide and other premium nutraceutical ingredients. www.andersongg.com
About ATM Metabolics, LLC:
ATM Metabolics, LLC, a Florida-based company, is a research firm focused on returning to the origins of drug discovery by exploring the metabolic and physiological pathways of plants in an effort to better understand how these unique systems may offer clues to creating better and safer therapeutics, especially related to carbohydrate (sugar) metabolism. www.atmmetabolics.com
Media Contact: Andrew Nagy VREV LIMITED, 866-924-6070, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE VREV LIMITED